CHANDIGARH: PGI will be one of the sites for the second and third phases of trials of Kovovax – a vaccine against Covid-19 – on children.
There will be 10 such sites in the country and PGI is one of them. “I was approached for the same. But we have to take approval from the ethics committee of the institute. Once that is done, we will be able to know how many subjects can be taken from our site for testing,” said Professor Madhu Gupta, principal investigator of the study at PGI.
The total sample size will be 920 and 460 each for the age group of 12 years and 17 years and 2 years and 11 years. Sources said that about 100 subjects will be allowed in PGI.
Last year, PGI was listed as one of 17 trial sites to conduct Phase II and III of human clinical trials CowishieldVaccine is developed by University of Oxford.
test will be started Serum Institute of India During this month when SII will seek approval from the Drug Controller General of India for Kovovax. Recombinant nanoparticle protein-based vaccine – NVXCoV2373 – developed by US biotechnology firm novavax Branded as Covovax in India. This will be the fourth COVID-19 vaccine to undergo clinical trials for children in India. Children will be followed for six months after having two shots of Kovovax spaced 21 days apart. The vaccine is expected to be launched by the end of this year.
There will be 10 such sites in the country and PGI is one of them. “I was approached for the same. But we have to take approval from the ethics committee of the institute. Once that is done, we will be able to know how many subjects can be taken from our site for testing,” said Professor Madhu Gupta, principal investigator of the study at PGI.
The total sample size will be 920 and 460 each for the age group of 12 years and 17 years and 2 years and 11 years. Sources said that about 100 subjects will be allowed in PGI.
Last year, PGI was listed as one of 17 trial sites to conduct Phase II and III of human clinical trials CowishieldVaccine is developed by University of Oxford.
test will be started Serum Institute of India During this month when SII will seek approval from the Drug Controller General of India for Kovovax. Recombinant nanoparticle protein-based vaccine – NVXCoV2373 – developed by US biotechnology firm novavax Branded as Covovax in India. This will be the fourth COVID-19 vaccine to undergo clinical trials for children in India. Children will be followed for six months after having two shots of Kovovax spaced 21 days apart. The vaccine is expected to be launched by the end of this year.
.